Kalmbach Thomas Peter sold $1.2M of GL

Kalmbach Thomas Peter (EVP & CFO) sold 7,936 shares of GLOBE LIFE INC. (GL) at $156.59 ($1.24M total) on 2026-05-22.

Original reporting
SEC EDGAR · Kalmbach Thomas Peter
Published May 26, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GL
Bearish
medium confidence
Mentioned
$GL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLBearishMed
01

Why it matters

The disclosure can influence short-term sentiment and options/flow positioning, but it does not provide new fundamentals or corporate actions.

02

Market read

Traders may treat this as a modest negative signal for GL sentiment, while awaiting any corroborating fundamental news.

03

What to watch

No 10b5-1 plan is cited, which can increase interpretive uncertainty; traders may also compare with prior insider activity frequency and size to gauge whether this is isolated.

Relevance 7/10Timing: Immediate (filed today); any price reaction typically fades quickly unless accompanied by other news.

Background

SEC Form 4 discloses insider transactions; this filing reports an open-market sale by Globe Life’s EVP & CFO.

Company-level read

Ticker impact

$GLBearishMedium confidence
Context

Globe Life CFO sold 7,936 shares in an open-market transaction for about $1.24M, per SEC Form 4 filed 2026-05-26.

Expected impact

Likely modest, short-lived negative bias; follow-through depends on whether selling is part of routine diversification or a broader trend.

Evidence & confidence

The article is limited to an SEC Form 4 sale (no 10b5-1 plan stated) and does not include earnings, M&A, or operational updates.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide regulatory or competitive shock.

None indicated; Globe Life is a US-listed insurer and the filing does not reference macro/regional events.

Low; no international transaction or cross-border catalyst mentioned.

Counterpoint

The sale may reflect routine personal liquidity needs or tax planning rather than a bearish view, especially since the filing lacks any stated performance or outlook rationale.

Key entities

  • Globe Life Inc.

    Subject of the insider transaction disclosure: EVP & CFO Kalmbach sold 7,936 shares for ~$1.24M.

  • Kalmbach Thomas Peter

    EVP & CFO who executed the open-market sale; holdings after transaction were 50,496 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEMedAI 8/10

Why Stocks Like Bloom Energy and Globe Life Slumped

Bloom Energy (BE) fell 8% despite a 138.9% revenue increase and EPS beat, due to concerns over future revenue and capital expenditure. Globe Life (GL) dropped 8% after reporting 5.3% revenue growth and warning of FY 2026 headwinds. Comfort Systems (FIX) declined 9.26% despite strong earnings and revenue growth, citing higher material costs.

$GLMed

Globe Life Inc (GL) Q3 2026 Earnings Call Highlights: Premium Growth and Buybacks Offset

Globe Life Inc (GL) reported Q3 2026 earnings with total premium revenue up 7%, health premium revenue up 16%, and book value per share rising 23%. The company returned $210M to shareholders and expects to return near 70% of full-year net operating income. However, net income decreased 2%, life underwriting margin fell 5%, and full-year 2026 net operating EPS guidance was reduced to $15.35-$15.65. Management discussed various challenges and strategic plans during the earnings call.

$GLMed

Piper Sandler cuts Globe Life stock rating on medical claims concerns

Piper Sandler downgraded Globe Life (NYSE:GL) to Neutral, lowering its price target to $165 from $200 due to concerns over medical claims volatility. The stock trades at $168.41 with a P/E ratio of 10.97. Q3 results showed revenue of $1.6B, beating estimates, but EPS missed at $4.84. The firm cited exposure to medical claims severity and irregularity in Medicare supplement claims as key issues.